Burling Wealth Partners LLC Sells 7,308 Shares of Zoetis Inc. $ZTS

Burling Wealth Partners LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 24.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,488 shares of the company’s stock after selling 7,308 shares during the quarter. Burling Wealth Partners LLC’s holdings in Zoetis were worth $2,829,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Northbridge Financial Group LLC bought a new stake in Zoetis in the 4th quarter valued at $300,000. Banque Cantonale Vaudoise increased its holdings in Zoetis by 8.3% in the 4th quarter. Banque Cantonale Vaudoise now owns 71,286 shares of the company’s stock valued at $8,970,000 after buying an additional 5,480 shares during the period. Fairtree Asset Management Pty Ltd increased its holdings in Zoetis by 82.1% in the 4th quarter. Fairtree Asset Management Pty Ltd now owns 29,265 shares of the company’s stock valued at $3,682,000 after buying an additional 13,194 shares during the period. Hudson Canyon Capital Management increased its holdings in Zoetis by 11.7% in the 4th quarter. Hudson Canyon Capital Management now owns 14,800 shares of the company’s stock valued at $1,862,000 after buying an additional 1,550 shares during the period. Finally, Harvest Portfolios Group Inc. increased its holdings in Zoetis by 4.4% in the 4th quarter. Harvest Portfolios Group Inc. now owns 416,270 shares of the company’s stock valued at $52,375,000 after buying an additional 17,497 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares in the company, valued at $1,906,986.24. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 11,650 shares of company stock worth $886,384 in the last ninety days. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $79.64 on Thursday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $172.23. The company has a market cap of $33.39 billion, a PE ratio of 13.21, a PEG ratio of 1.29 and a beta of 0.87. The company’s 50-day moving average is $109.69 and its two-hundred day moving average is $119.37.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the previous year, the company posted $1.48 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ZTS. William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Piper Sandler reissued a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. BTIG Research reissued a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $134.75.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.